Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. However, patients eventually develop drug resi...
Shranjeno v:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2015-09-01
|
| Serija: | Acta Pharmaceutica Sinica B |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S2211383515001045 |
| Oznake: |
Brez oznak, prvi označite!
|